Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Expenses for 6 consecutive years, with $42.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 46.1% to $42.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.7 million, a 53.21% increase, with the full-year FY2025 number at $167.7 million, up 53.21% from a year prior.
  • Operating Expenses was $42.4 million for Q4 2025 at Janux Therapeutics, down from $45.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $45.3 million in Q3 2025 to a low of $2.7 million in Q1 2021.
  • A 5-year average of $23.5 million and a median of $21.3 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 1433.6% in 2021, then fell 11.9% in 2023.
  • Janux Therapeutics' Operating Expenses stood at $15.1 million in 2021, then surged by 39.75% to $21.1 million in 2022, then fell by 11.9% to $18.6 million in 2023, then skyrocketed by 56.05% to $29.0 million in 2024, then soared by 46.1% to $42.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Operating Expenses are $42.4 million (Q4 2025), $45.3 million (Q3 2025), and $45.1 million (Q2 2025).